Looking into AOD-9604- does anyone have any first hand experience with it?

[FatPanda]

I just found out about AOD-9604, and I am eager to try it, perhaps while resting from KLOW and MOTS-C. However, I wanted to get some more opinions on it. Is it worth a try?

 

[AndyPanda]

I just found out about AOD-9604, and I am eager to try it, perhaps while resting from KLOW and MOTS-C. However, I wanted to get some more opinions on it. Is it worth a try?

I don’t think it does anything, and don’t know of anyone that’s actually benefited from it other than the people who sell the stuff.

 

[littledragon25]

Everything I've heard is that it's bunk and not to bother.

 

[Jack brown]

It's the study here: https://pmc.ncbi.nlm.nih.gov/articles/PMC3584306/
It has dosages of 0.25-1mg per day, and basically did nothing.

 

[Mr. Blonde]

Let me guess...guy pitching this shit offered a discount code?!

 

[Calm Logic]

Bumping with more info against the use of AOD, recommending alternatives instead like GLPs and GH peptides (sermorelin and tesamorelin):

Safety and Efficacy of Approved and Unapproved Peptide Therapies for
Musculoskeletal Injuries and Athletic Performance (2025)

AOD-9604 (Anti-Obesity Drug 9604) is a peptide fragment of residues 177-191 of human growth hormone (hGH), with a tyrosine residue added to enhance stability. AOD-9604 was originally developed to isolate the lipolytic properties of hGH while avoiding anabolic and insulin desensitizing effects. AOD-9604 is proposed to stimulate lipolysis through interaction with beta adrenergic receptors. AOD-9604 does not bind the hGH receptor with high affinity and does not stimulate insulin-like growth factor 1 (IGF-1) production, and aims to reduce adiposity without the other effects of chronic hGH administration.

AOD-9604 significantly reduced fat mass in rodent models of obesity, which then led to six randomized, double-blind, placebo-controlled trials involving over 900 patients to evaluate the treatment of obesity. The safety profile was favorable, with no changes in IGF-1 or insulin sensitivity. However, AOD-9604 failed to show dose dependent, statistically significant weight loss compared to placebo, leading to the termination of clinical development for obesity.

AOD-9604 is often promoted off-label for fat reduction, although it is ineffective for this purpose. Recently, there has been interest in AOD-9604 for cartilage repair based on promising results in a rabbit model of osteoarthritis, but there is no human data available. While clinical trials demonstrated AOD-9604 was safe in the short term, prolonged activation of beta adrenergic signaling could lead to dysautonomias.

Alternatives to AOD-9604 for weight loss include the GLP-1RAs, or the norepinephrine and dopamine releasing agent phentermine. The hGH secretagogues sermorelin and tesamorelin, discussed in subsequent sections, may also be appropriate alternatives. Physiotherapy, hyaluronic acid, platelet rich plasma (PRP), bone marrow aspirate concentrate (BMAC), or adipose stromovascular fraction (SVF) therapies are likely better at treating osteoarthritis symptoms.